ADMA Biologics Investigation: ADMA Biologics (ADMA) Investigated for Alleged Channel Stuffing – Contact BFA Law if You Suffered Losses

NEW YORK, June 10, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm  Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit.

GlobeNewsWire • 8 hours ago

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMA

New York, New York--(Newsfile Corp. - June 7, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA) resulting from allegations that ADMA Biologics may have issued materially misleading business information to the investing public. SO WHAT: If you purchased ADMA Biologics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Newsfile Corp • Jun 7, 2026

Adma Biologics (ADMA) Down 5.8% Since Last Earnings Report: Can It Rebound?

Adma Biologics (ADMA) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Jun 5, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA

NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

PRNewsWire • Jun 4, 2026

ADMA Legal Claims: ADMA Biologics may have Misrepresented its Revenue Sources to Investors – Contact BFA Law about its Pending Securities Fraud Investigation

NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm  Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit.

GlobeNewsWire • Jun 3, 2026

New Strong Sell Stocks for June 3rd

AOS, ADMA and AMTB have been added to the Zacks Rank #5 (Strong Sell) List on June 3rd, 2026.

Zacks Investment Research • Jun 3, 2026

ADMA Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA) resulting from allegations that ADMA Biologics may have issued materially misleading business information to the investing public.

GlobeNewsWire • Jun 2, 2026

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMA

New York, New York--(Newsfile Corp. - June 1, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA) resulting from allegations that ADMA Biologics may have issued materially misleading business information to the investing public. SO WHAT: If you purchased ADMA Biologics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Newsfile Corp • Jun 2, 2026

ADMA Biologics: Longstanding Bull Hits The Reset Button After Murky Q1 Earnings

ADMA Biologics (ADMA) faces IVIG market headwinds, flat Q1 revenue, and reduced 2026 guidance, leading to a >50% YTD share price decline. ASCENIV's differentiated profile drove 28% YoY revenue growth and record utilization, partially offsetting BIVIGAM's 54% decline amid IVIG pricing pressure. Gross margin expanded to 71%, adjusted EBITDA rose 24% YoY, and strong cash generation supports resilience despite market disruption.

Seeking Alpha • May 29, 2026

$ADMA Securities News: ADMA Biologics Investigated for Securities Fraud Over Channel Stuffing Allegations – Investors with Losses Notified to Contact BFA Law

NEW YORK, May 29, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm  Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit.

GlobeNewsWire • May 29, 2026